ES2596855T3 - Inducción de tolerancia mucosa a antígenos - Google Patents

Inducción de tolerancia mucosa a antígenos Download PDF

Info

Publication number
ES2596855T3
ES2596855T3 ES06830192.8T ES06830192T ES2596855T3 ES 2596855 T3 ES2596855 T3 ES 2596855T3 ES 06830192 T ES06830192 T ES 06830192T ES 2596855 T3 ES2596855 T3 ES 2596855T3
Authority
ES
Spain
Prior art keywords
acid
ova
microorganism
autoimmune
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06830192.8T
Other languages
English (en)
Inventor
Pieter Rottiers
Veerle Snoeck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intrexon Actobiotics NV
Original Assignee
Intrexon Actobiotics NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrexon Actobiotics NV filed Critical Intrexon Actobiotics NV
Application granted granted Critical
Publication of ES2596855T3 publication Critical patent/ES2596855T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/20—Feeding-stuffs specially adapted for particular animals for horses
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/50—Feeding-stuffs specially adapted for particular animals for rodents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Animal Husbandry (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)

Abstract

Una combinación que comprende un microorganismo secretor de IL-10 y un alérgeno, aloantígeno, antígeno propio o autoantígeno para su uso en la inducción de tolerancia inmunitaria o para su uso en el tratamiento de una enfermedad elegida del grupo que consiste en una reacción alérgica que incluye alergia alimentaria, enfermedad celíaca, asma alérgica, uveítis autoinmunitaria, tiroiditis autoinmunitaria, miastenia gravis autoinmunitaria, artritis reumatoide, diabetes tipo I, esclerosis múltiple, enfermedad de injerto contra huésped, inmunoactivación de producto terapéutico, y producción de anticuerpos contra el Factor VIII no endógeno, en un mamífero.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
vida restante del mamífero); por ejemplo desde aproximadamente (2 o 3 o 5 días, 1 o 2 semanas, o 1 mes) hacia arriba y/o por ejemplo hasta aproximadamente (5 años, 1 año, 6 meses, 1 mes, 1 semana, o 3 o 5 días). Es típica la administración de la dosis de mantenimiento diaria durante de aproximadamente 3 a aproximadamente 5 días o durante de aproximadamente 1 semana a aproximadamente 1 año. Otros constituyentes de las formulaciones
5 líquidas pueden incluir conservantes, sales inorgánicas, ácidos, bases, tampones, nutrientes, vitaminas u otros productos farmacéuticos.
El microorganismo que secreta el compuesto inmunomodulador y/o el antígeno puede administrarse en una dosis de al menos 104 unidades formadoras de colonias (ufc) a 1012 ufc al día, preferiblemente entre 106 ufc y 1012 ufc al día,
10 lo más preferiblemente entre 109 ufc y 1012 ufc al día. Según el método descrito en Steidler y col. (Science 2000), el compuesto inmunomodulador de por ejemplo de 109 ufc se secreta hasta de al menos 1 ng a 100 ng. A través de ELISA, conocido por un experto en la técnica, el antígeno de, por ejemplo, de 109 ufc se secreta hasta de al menos 1 ng a 100 ng; el experto en la técnica puede calcular el intervalo de secreción de compuesto inmunomodulador y/o antígeno en relación con cualquier otra dosis de ufc.
15 El antígeno puede administrarse en una dosis que induce una respuesta a baja dosis. Preferiblemente, dicho antígeno se administra en una dosis de al menos 10 fg a 100 µg al día, preferiblemente entre 1 pg y 100 µg al día, lo más preferiblemente entre 1 ng y 100 µg al día.
20 El compuesto inmunomodulador de la invención puede administrarse en una dosis de al menos 10 fg a 100 µg al día, preferiblemente entre 1 pg y 100 µg al día, mucho más preferiblemente entre 1 ng y 100 µg al día.
Preferiblemente, los compuestos o la composición se proporcionan en una forma farmacéutica unitaria, por ejemplo un comprimido, una solución, una cápsula o una dosis de aerosol medida, de modo que se administra una dosis 25 única al sujeto, por ejemplo un paciente.
Dependiendo del modo de administración, por ejemplo oral, o cualquiera de los descritos anteriormente, el experto en la técnica conoce cómo definir o calcular la dosis real que va a administrarse a un paciente. El experto en la técnica tendrá conocimientos sobre cómo ajustar las dosis dependiendo del paciente, el microorganismo, el vector,
30 etc.
Los compuestos de la presente invención también pueden tomar la forma de una sal, hidrato, solvato o metabolito farmacológicamente aceptable. Las sales farmacológicamente aceptables incluyen sales básicas de ácidos orgánicos e inorgánicos, incluyendo, pero sin limitación, ácido clorhídrico, ácido bromhídrico, ácido sulfúrico, ácido 35 fosfórico, ácido nítrico, ácido metanosulfónico, ácido etanosulfónico, ácido p-toluenosulfónico, ácido naftalenosulfónico, ácido málico, ácido acético, ácido oxálico, ácido tartárico, ácido cítrico, ácido láctico, ácido fumárico, ácido succínico, ácido maleico, ácido salicílico, ácido benzoico, ácido fenilacético, ácido mandélico y similares. Cuando los compuestos de la invención incluyen una función ácida, tal como un grupo carboxilo, entonces los expertos en la técnica conocen bien pares catiónicos farmacéuticamente aceptables para el grupo carboxilo e
40 incluyen cationes alcalinos, alcalinotérreos, de amonio, de amonio cuaternario y similares.
El microorganismo puede ser cualquier microorganismo, incluyendo bacterias, levaduras u hongos, adecuados para administración mucosa. Preferiblemente, dicho microorganismo es un microorganismo no patógeno, incluso más preferiblemente dicho microorganismo es un microorganismo probiótico. El experto en la técnica conoce organismos 45 probióticos. Los organismos probióticos incluyen, pero sin limitación, bacterias tales como Lactobacillus sp., Lactococcus sp., y levaduras tales como Saccharomyces cerevisiae subspecies boulardii. Preferiblemente, dicha bacteria es una bacteria de ácido láctico; incluso más preferiblemente, dicha bacteria de ácido láctico se elige entre el grupo que consiste en Lactobacillus, Leuconostoc, Pediococcus, Lactococcus, Streptococcus, Aerococcus, Carnobacterium, Enterococcus, Oenococcus, Teragenococcus, Vagococcus y Weisella. En una realización preferida
50 adicional, dicho microorganismo es Lactococcus lactis. En otras realización preferida, dicho microorganismo es Saccharomyces cerevisiae.
En una realización preferida, la citocina inmunosupresora se combina con anticuerpos antagonizantes contra citocinas inmunoinductoras, tales como anti-IL-2, anti-IL-12 y/o anti-IFNγ; y moléculas coestimuladoras, tales como 55 anti-CD40L y anti-CD3. Como alternativa, pueden administrarse compuestos que estimulan la producción de las citocinas inmunosupresoras, tales como subunidad B de la toxina del cólera; y moléculas que estimulan la función de linfocitos T reguladores, tales como agonistas de CTLA-4 e ICOS. Como se ha descrito anteriormente, preferiblemente, dicho microorganismo es un microorganismo no patógeno, incluso más preferiblemente es un microorganismo probiótico. El experto en la técnica conoce organismos probióticos, e incluyen, pero sin limitación,
9
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
Dos modelos de ratón de asma alérgica que imita a la enfermedad humana son el modelo de alérgeno Ova y el modelo SCID humanizado.
El modelo de alérgeno Ova
5 Se exponen mediante inhalación ratones sensibilizados a OVA con aerosol de OVA que conduce a inflamación eosinofílica de las vías respiratorias dependiente de citocinas Th2, hiperreactividad bronquial y producción de IgE, hallazgos ampliamente característicos del asma alérgica humana (Brusselle, 1994, Clin Exp Allergy 24: 73; Kips y col. 1996, Am J Respir Crit Care Med 153: 535; Brusselle y col. 1995, Am J Respir Cell Mol Biol 12: 254).
10
Bacterias
Se usa la cepa MG1363 de L. lactis a lo largo de todo este estudio. Se cultivan las bacterias en medio GM17, es decir, M17 (Difco Laboratories, Detroit, MI) complementado con glucosa al 0,5 %. Se almacenan las suspensiones
15 madre de todas las cepas a -20 ºC en glicerol al 50 % en GM17. Para inoculaciones intragástricas, se diluyen las suspensiones madre 200 veces en GM17 nuevo y se incuban a 30 ºC. Alcanzaron una densidad de saturación de 2 x 109 unidades formadoras de colonias (UFC) por ml en el plazo de 16 horas. Se recogen las bacterias mediante centrifugación y se concentran 10 veces en medio BM9. Para el tratamiento, cada ratón recibe 100 µl de esta suspensión diariamente mediante catéter intragástrico.
20
Plásmidos
Se recupera la secuencia de ARNm que codifica para ovoalbúmina de Gallus gallus de Genbank (número de registro AY223553). Se aísla ARN total de útero de pollo y se sintetiza ADNc usando 2 µg de ARN total, cebadores de oligo
25 dT2 µM (Promega Corporation Benelux, Leiden, Países Bajos), DTT 0,01 mM (Sigma-Aldrich, Zwijndrecht, Países Bajos), dNTP 0,5 mM (Invitrogen, Merelbeke, Bélgica), 20 U de Rnasin (Promega Incorporation Benelux) y 100 U de transcriptasa inversa Superscript II (Invitrogen) en un volumen de 25 µl. Se amplifica el fragmento de ADNc de OVA mediante reacción en cadena de la polimerasa (PCR) usando las siguientes condiciones: 94 ºC durante 2 min seguido de 30 ciclos a 94 ºC durante 45 segundos, 62 ºC durante 30 segundos y 72 ºC durante 90 segundos, con los
30 siguientes cebadores directo e inverso 5'-GGCTCCATCGGTGCAGCAAGCATGGAATT-3' y 5'-ACTAGTTAAGGGGAAAC-ACATCTGCCAAAGAAGAGAA-3'.
Se fusiona el fragmento amplificado a la señal de secreción Usp45 del vector pT1NX resistente a eritromicina, en el 35 sentido de 3' del promotor P1 de lactococos.
Las cepas MG1363 transformadas con plásmidos que portan IL-10 murina y ADNc de OVA se designan LL-IL10 y LL-OVA. LL-pT1NX, que es MG1363 que contiene el vector vacío pT1NX, sirven como control.
40 Cuantificación de OVA
Se determina OVA a partir de LL-OVA usando un ensayo inmunoabsorbente ligado a enzimas (ELISA) específico de OVA desarrollado en el laboratorio. También se evalúa la producción de las proteínas recombinantes mediante análisis de transferencia de tipo Western.
45
El modelo de alérgeno OVA
Ratones
50 Se adquieren ratones BALB/c (de 6 a 8 semanas de edad) de Charles River Laboratories (Calco, Italia). Se mantienen los ratones en condiciones libres de patógenos específicos.
Inmunización de los ratones
55 Se inmunizan los ratones por vía i.p. con 2 µg de OVA (calidad V; Sigma-Aldrich) en 2 mg de hidróxido de aluminio (alumbre). Se repite esta inmunización tras un intervalo de 10 días (en los días 0 y 10). Los ratones control reciben una inyección de solución salina en lugar de la disolución de OVA/alumbre. Siete días tras la inmunización, los ratones sensibilizados inhalan una disolución aerosolizada de OVA al 3 % disuelta en PBS durante 10 min. Se realiza la inhalación de OVA durante 3 días en una fila (días 18, 19, y 20). Los ratones control inhalan PBS solo en
18
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30

Claims (1)

  1. imagen1
    imagen2
    imagen3
ES06830192.8T 2005-11-29 2006-11-29 Inducción de tolerancia mucosa a antígenos Active ES2596855T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05111467 2005-11-29
EP05111467 2005-11-29
PCT/EP2006/069062 WO2007063075A1 (en) 2005-11-29 2006-11-29 Induction of mucosal tolerance to antigens

Publications (1)

Publication Number Publication Date
ES2596855T3 true ES2596855T3 (es) 2017-01-12

Family

ID=37889980

Family Applications (2)

Application Number Title Priority Date Filing Date
ES06830192.8T Active ES2596855T3 (es) 2005-11-29 2006-11-29 Inducción de tolerancia mucosa a antígenos
ES09169276T Active ES2405552T3 (es) 2005-11-29 2006-11-29 Inducción de tolerancia mucosa a antiantígenos de células beta de islotes pancreáticos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES09169276T Active ES2405552T3 (es) 2005-11-29 2006-11-29 Inducción de tolerancia mucosa a antiantígenos de células beta de islotes pancreáticos

Country Status (13)

Country Link
US (5) US8748126B2 (es)
EP (3) EP1957100B1 (es)
JP (2) JP5410759B2 (es)
CN (1) CN101316611B (es)
AU (1) AU2006319216B2 (es)
BR (1) BRPI0619206A2 (es)
CA (1) CA2631598C (es)
DK (1) DK2119450T3 (es)
ES (2) ES2596855T3 (es)
HK (1) HK1231371A1 (es)
PT (1) PT2119450E (es)
RU (1) RU2420569C2 (es)
WO (1) WO2007063075A1 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780961B2 (en) 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
AU2006319216B2 (en) 2005-11-29 2012-09-13 Intrexon Actobiotics Nv Induction of mucosal tolerance to antigens
DK2347775T3 (da) 2005-12-13 2020-07-13 Harvard College Skabeloner til celletransplantation
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
WO2008071751A1 (en) * 2006-12-14 2008-06-19 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
EP3351268B1 (en) 2007-01-25 2020-08-05 Intrexon Actobiotics NV Treatment of immune disease by mucosal delivery of antigens
US9770535B2 (en) 2007-06-21 2017-09-26 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
FI20075539A7 (fi) * 2007-07-12 2009-01-13 Valio Oy Maitohappobakteerit, joilla on proinflammatorisia ominaisuuksia
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
CN102006891B (zh) 2008-02-13 2017-04-26 哈佛学院董事会 连续的细胞程序化装置
EP2331124A1 (en) 2008-08-15 2011-06-15 Circassia Limited T-cell antigen peptide from allergen for stimulation of il-10 production
ES2378870T5 (es) 2008-08-15 2016-02-03 Circassia Limited Vacuna que comprende péptidos Amb a 1 para uso en el tratamiento de alergia a ambrosía
WO2010056143A1 (en) * 2008-11-13 2010-05-20 Instituto De Medicina Molecular The use of adjuvant to facilitate the induction of immune tolerance
ES2532759T3 (es) 2009-02-05 2015-03-31 Circassia Limited Péptidos de plantas herbáceas para vacunas
US10617640B2 (en) 2009-07-07 2020-04-14 The Research Foundation For The State University Of New York Phosphoserine containing compositions for immune tolerance induction
EP2451485B1 (en) * 2009-07-07 2016-03-02 The Research Foundation Of State University Of New York Lipidic compositions for induction of immune tolerance
US8728456B2 (en) 2009-07-31 2014-05-20 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
US20110081320A1 (en) * 2009-10-06 2011-04-07 Nubiome, Inc. Treatment/Cure of Autoimmune Disease
WO2011111734A1 (ja) 2010-03-10 2011-09-15 株式会社カネカ 乳酸菌含有製剤
WO2011150235A1 (en) * 2010-05-27 2011-12-01 Allertein Therapeutics, Llc Methods and reagents for treating autoimmune disorders and/or graft rejection
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
EP3620185A1 (en) 2010-10-06 2020-03-11 President and Fellows of Harvard College Injectable, pore-forming hydrogels for materials-based cell therapies
ES2685327T3 (es) 2011-04-28 2018-10-08 President And Fellows Of Harvard College Armazones tridimensionales macroscópicos preformados inyectables para administración mínimamente invasiva
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
AU2012261848B2 (en) 2011-06-03 2017-06-15 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
CA2848471C (en) 2011-09-23 2021-11-16 Actogenix Nv Modified gram positive bacteria and uses thereof
DK2758512T3 (en) 2011-09-23 2018-07-23 Intrexon Actobiotics Nv MODIFIED GRAM POSITIVE BACTERIES AND APPLICATIONS THEREOF
CA2863532A1 (en) * 2012-02-08 2013-08-15 Premune Ab Prevention of inflammatory disorders in domestic non-human mammals
PT2838515T (pt) 2012-04-16 2020-02-25 Harvard College Composições de sílica mesoporosa para modular respostas imunológicas
EP4541818A3 (en) * 2012-05-25 2025-07-23 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
JP6219728B2 (ja) * 2014-01-15 2017-10-25 キッコーマン株式会社 Ｆｏｘｐ３陽性制御性Ｔ細胞とＩＦＮ−γ産生ＩＬ−１０産生Ｔ細胞誘導を指標とした、経口免疫寛容物質スクリーニング方法及び経口免疫寛容増強組成物
KR20240154672A (ko) * 2014-02-21 2024-10-25 에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) 글리코타겟팅 치료제
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
EP3137105A4 (en) 2014-04-30 2017-12-27 President and Fellows of Harvard College Combination vaccine devices and methods of killing cancer cells
EP2989904A1 (en) * 2014-07-29 2016-03-02 Heinrich-Heine-Universität Induction of immunological tolerance using yeast
KR101662898B1 (ko) * 2014-09-02 2016-10-06 서울대학교산학협력단 점막점착성 고분자 및 이의 용도
EP3237622B1 (en) 2014-12-23 2021-02-24 Ilya Pharma AB Methods for wound healing
US10363288B2 (en) 2015-01-14 2019-07-30 National Jewish Health Insulin mimotopes and methods of using the same
HK1247861A1 (zh) 2015-01-30 2018-10-05 President And Fellows Of Harvard College 用於癌症治疗的肿瘤周围和肿瘤内部材料
CN114099793A (zh) 2015-04-10 2022-03-01 哈佛学院院长等 免疫细胞捕获装置及其制备和使用方法
EP3081227A1 (en) * 2015-04-15 2016-10-19 Institut National De La Recherche Agronomique Lactococcus lactis producing tslp or il-25 and their uses as probiotics and therapeutics
US10857190B2 (en) * 2015-10-06 2020-12-08 Albert Einstein College Of Medicine Microbial hyperswarmers and uses thereof
CN115487351A (zh) 2016-02-06 2022-12-20 哈佛学院校长同事会 重塑造血巢以重建免疫
EP3484448B1 (en) 2016-07-13 2025-04-09 President and Fellows of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
RU2770060C2 (ru) 2016-08-02 2022-04-14 Президент Энд Феллоуз Оф Гарвард Колледж Биологические материалы для модуляции иммунных ответов
AU2017319707B2 (en) 2016-09-02 2023-11-09 Intrexon Actobiotics N.V. Genetically modified bacteria stably expressing IL-10 and insulin
EP3512872A1 (en) 2016-09-13 2019-07-24 Intrexon Actobiotics NV Mucoadhesive microorganism
CN108114272B (zh) * 2016-11-28 2026-01-06 上海市第五人民医院 一种构建哮喘免疫耐受模型的方法
WO2019067871A2 (en) * 2017-09-29 2019-04-04 Nantcell, Inc. ANTIGENIC PROTEINS AND ASSOCIATED METHODS
US11052060B2 (en) 2018-02-12 2021-07-06 The Regents Of The University Of Colorado, A Body Corporate Compounds and methods for treating autoimmunity
US11013707B2 (en) 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa
JP2020000033A (ja) * 2018-06-26 2020-01-09 国立大学法人広島大学 経口免疫寛容誘導剤、これを含有する食品および医薬品、ならびに加工食品の製造方法
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
CN110408579A (zh) * 2019-06-03 2019-11-05 东北农业大学 牛白细胞介素-2重组乳酸菌及其应用
EP4034148A4 (en) 2019-09-23 2025-09-10 Harvard College BIOMATERIAL-BASED ANTIGEN-FREE VACCINE AND ITS USE
AU2020356592A1 (en) 2019-09-27 2022-04-07 Intrexon Actobiotics Nv D/B/A Precigen Actobio Treatment of celiac disease
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
US11762563B1 (en) 2021-01-28 2023-09-19 Board Of Trustees Of The University Of Alabama, For And On Behalf Of The University Of Alabama In Huntsville Systems and methods for improving radiation tolerance of memory
WO2022251253A1 (en) 2021-05-24 2022-12-01 Provention Bio, Inc. Methods for treating type 1 diabetes

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4100495A (en) 1975-11-27 1978-07-11 Cselt - Centro Studi E Laboratori Telecomunicazioni Adaptive method of and means for recovering digital signals
US4190495A (en) 1976-09-27 1980-02-26 Research Corporation Modified microorganisms and method of preparing and using same
US4874702A (en) 1980-09-08 1989-10-17 Biogen, Inc. Vectors and methods for making such vectors and for expressive cloned genes
US4888170A (en) 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
US5417986A (en) 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US5032510A (en) 1984-09-26 1991-07-16 Eli Lilly And Company Method for expression and secretion in bacillus
EP0176320B1 (en) 1984-09-26 1990-07-25 Eli Lilly And Company A method for expression and secretion in bacillus
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
EP0347425B1 (en) 1987-03-02 1995-12-27 Whitehead Institute For Biomedical Research Recombinant mycobacterial vaccine
US5591632A (en) 1987-03-02 1997-01-07 Beth Israel Hospital Recombinant BCG
US5330753A (en) 1987-04-29 1994-07-19 President And Fellows Of Harvard College Cholera vaccines
US6130082A (en) 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
US5972685A (en) 1988-07-21 1999-10-26 Iowa State University Research Foundation, Inc. Oral administration of coprostanol producing microorganisms to humans to decrease plasma cholesterol concentration
IE892131A1 (en) 1989-06-30 1991-01-02 Univ Cork Marker genes for genetic manipulation
US5149532A (en) 1989-11-01 1992-09-22 Cedars Sinai Medical Center Method of vaccine or toxoid preparation and immunization by colonization with recombinant microorganisms
DE4006521A1 (de) 1990-03-02 1991-09-05 Bayer Ag Zuckerhaltige polymere zur umhuellung und einbettung von arzneistoffen
GB9006400D0 (en) 1990-03-22 1990-05-23 Ciba Geigy Ag Bacterial vectors
IL99097A0 (en) 1990-09-05 1992-07-15 Akzo Nv Haemophilus paragallinarum vaccine
ATE180280T1 (de) 1991-03-05 1999-06-15 Wellcome Found Expression rekombinanter proteine in attenuierten bakterien
EP0607278B1 (en) 1991-10-07 2002-04-17 The Brigham And Women's Hospital, Inc. Method for enhancing gut absorption
IL103530A0 (en) 1991-10-25 1993-03-15 Duphar Int Res Treponema hyodysenteriae vaccine
US6221648B1 (en) 1992-02-27 2001-04-24 Microdial Technics Ltd. Heterologous gene expression in lactococcus, and the expression products therefrom
US5455034A (en) 1992-06-26 1995-10-03 Kansas State University Research Foundation Fusobacterium necrophorum leukotoxoid vaccine
DE4231764A1 (de) 1992-09-23 1994-03-24 Inst Pflanzengenetik & Kultur Verfahren zur chromosomalen Integration eines Produkt-Gens
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5691185A (en) 1993-10-08 1997-11-25 Chr. Hansen A/S Lactic acid bacterial suppressor mutants and their use as selective markers and as means of containment in lactic acid bacteria
CA2173751A1 (en) 1993-10-13 1995-04-20 Sýren Molin Recombinant staphylococcal nucleases and their use in limiting the survival of genetically engineered microorganisms
IT1270123B (it) 1994-10-05 1997-04-28 Dompe Spa Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia
US5733540A (en) 1995-03-08 1998-03-31 Lee; Peter Poon-Hang Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria
WO1996032486A1 (en) 1995-04-11 1996-10-17 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Method for the construction of vectors for lactic acid bacteria like lactobacillus such that the bacteria can efficiently express, secrete and display proteins at the surface
US5753622A (en) 1995-05-10 1998-05-19 University Technologies International, Inc. Use of epidermal growth factor as a gastrointestinal therapeutic agent
WO1996040947A1 (en) 1995-06-07 1996-12-19 Washington University Recombinant bacterial system with environmentally limited viability
US5824538A (en) 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
GB9518323D0 (en) 1995-09-07 1995-11-08 Steidler Lothar Materials and methods relating to the attachment and display of substances on cell surfaces
GB9521568D0 (en) 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
BR9708387A (pt) * 1996-03-28 2000-01-04 Genitrix Llc Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
EP0904072A4 (en) 1996-04-12 2003-07-30 Peptide Technology Pty Ltd METHOD FOR TREATING IMMUNO PATHOLOGIES USING MULTIPLE UNSATURATED FETAL ACIDS
US6261561B1 (en) 1996-04-19 2001-07-17 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of stimulating an immune response by administration of host organisms that express intimin alone or as a fusion protein with one or more other antigens
US5972887A (en) 1996-09-19 1999-10-26 The Nemours Foundation Treatment of intestinal epithelial cell malfunctions with Hepatocyte Growth Factor
US5723245A (en) 1996-10-09 1998-03-03 Xerox Corporation Colored toner and developer compositions and process for enlarged color gamut
US7361331B2 (en) * 1996-10-18 2008-04-22 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Plant bioreactors
GB9700939D0 (en) 1997-01-17 1997-03-05 Microbial Technics Limited Therapy
US6685943B1 (en) 1997-01-21 2004-02-03 The Texas A&M University System Fibronectin binding protein compositions and methods of use
PT892054E (pt) 1997-06-20 2007-02-28 Intervet Int Bv Vacina de clostridium perfringens
US6100388A (en) 1998-03-16 2000-08-08 Biogaia Biologies Ab Lactobacilli harboring aggregation gene as a vaccine delivery vehicle
EP2180050B1 (en) 1998-05-07 2016-04-20 Universite Libre De Bruxelles Cytotoxin-based biological containment
US6190669B1 (en) 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
KR100695562B1 (ko) 1998-09-28 2007-03-15 워너-램버트 캄파니 엘엘씨 Ｈｐｍｃ 캡슐을 이용한 장 및 결장에의 전달방법
WO2000022909A2 (en) 1998-10-19 2000-04-27 Biotech Australia Pty. Limited Systems for oral delivery
ATE259829T1 (de) 1998-10-20 2004-03-15 Vlaams Interuniv Inst Biotech Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis
PT1739178E (pt) 1999-07-05 2010-11-17 Actogenix Nv Libertação de péptidos trifólios
PT1356073E (pt) 2000-10-20 2010-02-15 Bioneer As Método de fermentação aperfeiçoado para a produção de produtos genéticos heterólogos em bactérias do ácido láctico
US7780961B2 (en) 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
AU2002314040B2 (en) * 2001-05-03 2007-06-28 Intrexon Actobiotics Nv Self-containing lactococcus strain
NO318426B1 (no) 2001-10-02 2005-04-18 Neurozym Biotech As Et materiale for a senke konsentrasjonen av patogene tarmpeptider
EP1319410A1 (en) 2001-12-11 2003-06-18 Société des Produits Nestlé S.A. Use of micro-organisms for a directed delivery of substances to specific parts of the gut
US20040043003A1 (en) 2002-01-31 2004-03-04 Wei Chen Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions
DE10208653A1 (de) 2002-02-28 2003-09-18 Medinnova Ges Med Innovationen Mikroorganismus als Träger von Nukleotidsequenzen kodierend für Zellantigene zur Behandlung von Tumoren
US7425449B2 (en) 2002-04-30 2008-09-16 The Regents Of The University Of California Site specific Listeria integration vectors and methods for using the same
AU2003234597A1 (en) 2002-05-14 2003-12-02 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
WO2004045392A2 (en) 2002-11-20 2004-06-03 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic method for celiac sprue
EP1364586A1 (en) * 2002-05-24 2003-11-26 Nestec S.A. Probiotics and oral tolerance
WO2004001020A2 (en) 2002-06-19 2003-12-31 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Methods and means to promote gut absorption
CA2506031A1 (en) 2002-11-15 2004-06-03 Vib Vzw Self-containing lactobacillus strain comprising a thya mutation and therapeutic applications thereof
JP4589618B2 (ja) * 2003-11-28 2010-12-01 独立行政法人農業生物資源研究所 免疫調節性機能を誘導する乳酸菌類とその成分
JP2007520566A (ja) * 2004-02-04 2007-07-26 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク 自己免疫治療のための抗ｃｄ３及び抗原特異的免疫療法
CN1695469A (zh) 2005-05-17 2005-11-16 田星 一种风味益生发酵乳及其制作方法
AU2006319216B2 (en) 2005-11-29 2012-09-13 Intrexon Actobiotics Nv Induction of mucosal tolerance to antigens
EP3351268B1 (en) 2007-01-25 2020-08-05 Intrexon Actobiotics NV Treatment of immune disease by mucosal delivery of antigens

Also Published As

Publication number Publication date
US20170100475A1 (en) 2017-04-13
EP1957100A1 (en) 2008-08-20
HK1231371A1 (en) 2017-12-22
AU2006319216A1 (en) 2007-06-07
US20140322230A1 (en) 2014-10-30
US8398995B2 (en) 2013-03-19
RU2420569C2 (ru) 2011-06-10
EP3097924B1 (en) 2020-01-08
CA2631598C (en) 2017-06-27
US20140322266A1 (en) 2014-10-30
JP5410759B2 (ja) 2014-02-05
ES2405552T3 (es) 2013-05-31
JP2013189446A (ja) 2013-09-26
AU2006319216B2 (en) 2012-09-13
WO2007063075A1 (en) 2007-06-07
EP3097924A1 (en) 2016-11-30
US8748126B2 (en) 2014-06-10
CN101316611A (zh) 2008-12-03
PT2119450E (pt) 2013-04-26
US9526750B2 (en) 2016-12-27
US20100172920A1 (en) 2010-07-08
US10195269B2 (en) 2019-02-05
DK2119450T3 (da) 2013-05-06
US20090148389A1 (en) 2009-06-11
EP2119450A3 (en) 2010-06-30
CN101316611B (zh) 2017-05-03
EP1957100B1 (en) 2016-07-13
CA2631598A1 (en) 2007-06-07
EP2119450A2 (en) 2009-11-18
EP2119450B1 (en) 2013-02-13
RU2008126198A (ru) 2010-01-10
US9539291B2 (en) 2017-01-10
JP2009521406A (ja) 2009-06-04
BRPI0619206A2 (pt) 2011-09-20

Similar Documents

Publication Publication Date Title
Vandenbroucke et al. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice
ES2405552T3 (es) Inducción de tolerancia mucosa a antiantígenos de células beta de islotes pancreáticos
US10500237B2 (en) Compositions comprising bacterial strains
EP3204025B1 (en) Compositions comprising bacterial strains
Sun et al. Display of Eimeria tenella EtMic2 protein on the surface of Saccharomyces cerevisiae as a potential oral vaccine against chicken coccidiosis
Wu et al. Immunomodulatory effects of IL-12 secreted by Lactococcus lactis on Th1/Th2 balance in ovalbumin (OVA)-induced asthma model mice
Huang et al. Astragaloside IV attenuates allergic inflammation by regulation Th1/Th2 cytokine and enhancement CD4+ CD25+ Foxp3 T cells in ovalbumin-induced asthma
Chang et al. Alteration of IL-17 related protein expressions in experimental autoimmune myocarditis and inhibition of IL-17 by IL-10-Ig fusion gene transfer
Bai et al. A single vaccination of nucleoside-modified Rabies mRNA vaccine induces prolonged highly protective immune responses in mice
Charng et al. Inhibition of allergen-induced airway inflammation and hyperreactivity by recombinant lactic-acid bacteria
JP2006525313A (ja) 視床下部−脳下垂体−副腎軸過敏性により特徴付けられる非定型うつ病及び他の疾患の治療のプロバイオティック
KR101291960B1 (ko) 장내세균에 의한 생물학적 활성제의 제어된 생산 및 전달
Yang et al. Construction and immunological evaluation of recombinant Lactobacillus plantarum expressing SO7 of Eimeria tenella fusion DC-targeting peptide
CN101918029B (zh) 免疫原性制剂
Guan et al. Targeting IL‐23 by employing a p40 peptide‐based vaccine ameliorates murine allergic skin and airway inflammation
Cheng et al. Blockade of IL-23 ameliorates allergic lung inflammation via decreasing the infiltration of Tc17 cells
Wang et al. Allergen specific immunotherapy enhanced defense against bacteria via TGF-β1-induced CYP27B1 in asthma
Guo et al. The construction and immunoadjuvant activities of the oral interleukin-17B expressed by lactobacillus plantarum NC8 strain in the infectious bronchitis virus vaccination of chickens
Chen et al. A bovine whey protein extract can induce the generation of regulatory T cells and shows potential to alleviate asthma symptoms in a murine asthma model
Xiong et al. IL-27 overexpression alleviates inflammatory response in allergic asthma by inhibiting Th9 differentiation and regulating Th1/Th2 balance
Tazaki et al. Allergen rush immunotherapy increases interleukin (IL)-12 production and IL-12 receptor β2 chain expression in patients with allergic asthma
Xu et al. Intranasal administration of recombinant mycobacterium smegmatis inducing IL-17A autoantibody attenuates airway inflammation in a murine model of allergic asthma
JP2019501926A (ja) 家塵ダニ由来アレルゲンによる過敏反応免疫調節剤
JP2016521567A (ja) 半生呼吸器合胞体ウイルスワクチン
TWI850940B (zh) 重組乳酸菌及其用於同時治療及/或預防塵蟎及蟑螂過敏症之用途